Entries |
Document | Title | Date |
20080227862 | Methods of treating cancer with HDAC inhibitors - The present invention relates to methods of treating cancers, e.g., leukemia. More specifically, the present invention relates to methods of treating acute and chronic leukemias including Acute Lymphocytic Leukemia (ALL), Acute Myeloid Leukemia (AML), Chronic Lymphocytic leukemia (CLL), Chronic myeloid leukemia (CML) and Hairy Cell Leukemia, by administration of pharmaceutical compositions comprising HDAC inhibitors, e.g., suberoylanilide hydroxamic acid (SAHA). The oral formulations of the pharmaceutical compositions have favorable pharmacokinetic profiles such as high bioavailability and surprisingly give rise to high blood levels of the active compounds over an extended period of time. The present invention further provides a safe, daily dosing regimen of these pharmaceutical compositions, which is easy to follow, and which results in a therapeutically effective amount of the HDAC inhibitors in vivo. | 09-18-2008 |
20080234384 | BIARYL AND BIHETEROARYL COMPOUNDS USEFUL IN TREATING IRON DISORDERS - This invention is directed to compounds of formula (I): | 09-25-2008 |
20080242730 | Hydroxamic Acid Derivatives and the Preparation Method Thereof - The present invention provides hydroxamic acid derivatives represented by the formula, having antioxidation, collagen biosynthesis promotion and skin pore contraction effects, and a method for preparation thereof. Further, the present invention provides skin-care external compositions for preventing skin aging, containing said hydroxamic acid derivatives represented by the formula as an active ingredient. | 10-02-2008 |
20080249180 | MALONAMIDES AS OREXIN ANTAGONISTS - The present invention relates to compounds of formula I | 10-09-2008 |
20080269342 | Pleuromutilin Derivatives and Its Use - The invention is directed to the L-tartrate salt of trans-3-aminocyclobutyl (1S,2R,3S,4S,6R,7R,8,14R)-4-ethenyl-3-hydroxy-2,4,7,14-tetramethyl-9-oxotricyclo[5.4.3.01,8]tetradec-6-yl imidodicarbonate (Compound IA.) Compound IA is useful for the treatment of a variety of diseases and conditions, such as respiratory tract and skin and skin structure infections. Accordingly, the invention is further directed to pharmaceutical compositions comprising Compound IA. The invention is still further directed to methods of treating respiratory tract and skin and skin structure infections using Compound IA or a pharmaceutical composition comprising Compound IA. | 10-30-2008 |
20080269343 | GALENIC FORMULATIONS OF ORGANIC COMPOUNDS - The present invention relates to a solid oral dosage form comprising a therapeutically effective amount of aliskiren or a pharmaceutically acceptable salt thereof, and wherein the active ingredient is present in an amount of more than 46% by weight based on the total weight of the oral dosage form. | 10-30-2008 |
20080275128 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATORY CONDITIONS - Embodiments of the invention relate to methods and compositions for treating symptoms related to inflammatory conditions and to methods and compositions for treating inflammatory components of common cold, utilizing various method of administration of X-ray contrast media (CM). | 11-06-2008 |
20080280987 | Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases - The invention provides methods of inhibiting angiogenesis in an individual by administering a composition (such as protein containing composition) comprising colchicine or thiocolchicine dimer. The composition is in an amount that is effective in inhibiting angiogenesis but is in some embodiments insufficient to induce significant cytotoxicity in the individual. The methods described herein are useful for treating angiogenesis-associated diseases, such as age-related macular degeneration, diabetic retinopathy, rheumatic arthritis, psoriasis, and cancer. | 11-13-2008 |
20080280988 | Use of (N'-Methyl) benzoylurea compound - The present invention provides, as novel use of a certain (N′-methyl)benzoylurea compound in soil treatment for protecting the aerial part of a plant from damage by a pest, a method for protecting the aerial part of a plant from damage by a pest, which comprises a step of applying a (N′-methyl)benzoylurea compound represented by the formula (I): | 11-13-2008 |
20080287545 | Use of Peptide Compounds For the Prophylaxis and Treatment of Chronic Headache - The present invention is directed to the use of a class of peptide compounds for the prophylaxis and treatment of chronic headache, particularly migraines. | 11-20-2008 |
20080287546 | Quorum Sensing Modulators - Compounds described herein are useful in modulating bacterial quorum sensing. | 11-20-2008 |
20080319081 | Insecticidal Compositions Having Improved Effect - The present invention relates to increasing the activity of crop protection compositions comprising phthalic acid diamides through the addition of ammonium salts and/or phosphonium salts or through the addition of ammonium or phosphonium salts and penetrants, to the corresponding compositions, to processes for preparing them and to their use in crop protection. | 12-25-2008 |
20090005453 | Crystalline forms of tigecycline and processes for preparation thereof - The present invention provides crystalline forms of Tigecycline, and methods of for preparation of crystalline forms and amorphous. | 01-01-2009 |
20090036537 | AROMATIC TRIAMIDE-LANTHANIDE COMPLEXES - The present invention provides luminescent lanthanide metal chelates comprising a metal ion of the lanthanide series and a complexing agent comprising at least one phthalamidyl moiety. Also provided are probes incorporating the phthalamidyl ligands of the invention and methods utilizing the ligands of the invention and probes comprising the ligands of the invention. | 02-05-2009 |
20090042992 | Polymorphs of suberoylanilide hydroxamic acid - The present invention provides methods of selectively inducing terminal differentiation, cell growth arrest and/or apoptosis of neoplastic cells, and/or inhibiting histone deacetylase (HDAC) by administration of pharmaceutical compositions comprising potent HDAC inhibitors. The oral bioavailability of the active compounds in the pharmaceutical compositions of the present invention is surprisingly high. Moreover, the pharmaceutical compositions unexpectedly give rise to high, therapeutically effective blood levels of the active compounds over an extended period of time. The present invention further provides a safe, daily dosing regimen of these pharmaceutical compositions, which is easy to follow, and which results in a therapeutically effective amount of the HDAC inhibitors in vivo. The present invention also provides a novel Form I polymorph of SAHA, characterized by a unique X-ray diffraction pattern and Differential Scanning Calorimetry profile, as well a unique crystalline structure. | 02-12-2009 |
20090062395 | RENIN INHIBITORS FOR THE TREATMENT OF HYPERTENSION - The present invention relates to methods for the prevention of, delay progression to or treatment of hypertension, comprising administering to a warm-blooded animal a therapeutically effective amount of a renin inhibitor or a pharmaceutically acceptable salt thereof as well as methods of preventing secondary complications linked to cessation of the treatment of hypertension. | 03-05-2009 |
20090069430 | DIBENZENE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS - The invention is directed to a compound of formula (I) | 03-12-2009 |
20090076153 | DEUTERIUM-ENRICHED TIGECYCLINE - The present application describes deuterium-enriched tigecycline, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 03-19-2009 |
20090076154 | DEUTERIUM-ENRICHED VORINOSTAT - The present application describes deuterium-enriched vorinostat, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 03-19-2009 |
20090082458 | DEUTERIUM-ENRICHED ALISKIREN - The present application describes deuterium-enriched aliskiren, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 03-26-2009 |
20090088479 | SALT OF ALISKIREN WITH SULFURIC ACID - The invention relates to a new salt of aliskiren, the respective production and usage, and pharmaceutical preparations containing such a salt. | 04-02-2009 |
20090118375 | Optically active phthalamides - Novel optically active phthalamides of the formula (I) in which A, q, R | 05-07-2009 |
20090131528 | SALT - The invention relates to a new salt of aliskiren, the respective production and usage, and pharmaceutical preparations containing such a salt. | 05-21-2009 |
20090143471 | Process for the Atomization of Ioxilan - The invention relates to a process for the preparation of ioxilan of formula 5-[N-(2,3-dihydroxypropyl)acetamido]-2,4,6-triiodo-N-(2,3-dihydroxypropyl)-N′-(2-hydroxyethyl)isophthalamide by atomization and to the improved product thus obtained. This process makes it possible to avoid a process by crystallization and results in an active principle having an improved solubility. | 06-04-2009 |
20090143472 | INTERMEDIATE COMPOUNDS AND THEIR USE IN PREPARATION OF LACOSAMIDE - The present invention is concerned with novel compounds and their use for the preparation of lacosamide. The present invention also contemplates processes for the preparation of lacosamide employing the novel compound of general Formula II, Formula IIa or Formula IIb as intermediate. | 06-04-2009 |
20090163595 | Method of Modulating Membrane Potential of a Cell - Provided herein are methods of modulating membrane potential of a cell membrane using self-assembling compounds. Also provided herein are methods of regulating a natural voltage-dependent ion channel in a cell membrane using the self-assembling compounds disclosed herein. Further provided herein are methods of treating, preventing and/or managing a disease that is related to the abnormal membrane potential responses by using the self-assembling compounds disclosed herein. | 06-25-2009 |
20090221713 | APOE MIMETIC AGENTS - The invention provides low molecular weight apoE mimetic agents suitable for preparing a medicament to treat autoimmune, inflammatory or neurodegenerative disease, (X) | 09-03-2009 |
20090292024 | SUBSTITUTED PROPANAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME - It is an object of the present invention to provide a substituted propanamide derivative or a pharmacologically acceptable salt thereof that is useful as a prophylactic or therapeutic agent for a bone metabolic disease. The present invention relates to a pharmaceutical composition comprising a compound having General Formula (I) or a pharmacologically acceptable salt thereof as an active ingredient: | 11-26-2009 |
20090298947 | POLYMORPHIC AND AMORPHOUS FORMS OF LACOSAMIDE AND AMORPHOUS COMPOSITIONS - The present invention relates to polymorphic and amorphous forms of Lacosamide, processes of preparing the polymorphic and amorphous forms, pharmaceutical compositions containing the same, therapeutic uses thereof and methods of treatment employing the same. | 12-03-2009 |
20100029774 | ALISKIREN MONOFUMARATE AND PROCESSES FOR PREPARATION THEREOF - The present invention provides a novel fumarate compound of aliskiren monofumarate, and process for preparation thereof. The present invention also provides pharmaceutical compositions comprising aliskiren monofumarate, and methods of using aliskiren monofumarate for treating hypertension. | 02-04-2010 |
20100029775 | RENIN INHIBITORS FOR THE PREVENTION AND TREATMENT OF HYPERTENSION IN OBESE PATIENTS - The present invention relates to methods for the prevention of, delay progression to or treatment of hypertension in obese patients, comprising administering to a warm-blooded animal a therapeutically effective amount of a renin inhibitor or a pharmaceutically acceptable salt thereof. | 02-04-2010 |
20100048715 | INSECTICIDAL COMPOUNDS - A compound of formula (I), wherein A | 02-25-2010 |
20100048716 | CRYSTALLINE FORMS OF ALISKIREN HEMIFUMARATE - This invention relates to crystal forms of aliskiren hemifumarate and various embodiments related thereto, e.g. pharmaceutical preparations, processes for the manufacture of the crystal forms, pharmaceuticals uses and the like. The crystal forms have particularly advantageous properties e.g. they are useful in the manufacture of blood-pressure lowering pharmaceutical preparations and the like. | 02-25-2010 |
20100087542 | IMPROVEMENT OF THE BIOLOGICAL ACTION OF AGROCHEMICAL COMPOSITIONS WHEN APPLIED TO THE CULTIVATION SUBSTRATE, SUITABLE FORMULATIONS AND USE THEREOF - In soil application, the action of crop protection compositions comprising active compounds from the class of the insecticidal phthalic acid diamides can be improved by adjuvants. The present invention describes corresponding methods and suitable compositions. | 04-08-2010 |
20100099770 | METHOD FOR TREATING DIABETIC PERIPHERAL NEUROPATHIC PAIN - The present invention concerns the novel use of compounds of the Formula I: for treating allodynia as major and unique pain symptom independent of the nature of an underlying disease, but that is often related to neuropathic pain or other different types of chronic or phantom pain. | 04-22-2010 |
20100113601 | METHOD FOR DECREASING SEBUM PRODUCTION - The present invention is directed to the topical application of the malonamide ACAT inhibitors described by Formula I. Other aspects of the invention are directed to topical formulations of these diamides, their use to treat sebaceous gland disorders and their use to alleviate oily skin. | 05-06-2010 |
20100120920 | N-ACETYLCYSTEINE AMIDE (NAC AMIDE) FOR THE TREATMENT OF DISEASES AND CONDITIONS ASSOCIATED WITH OXIDATIVE STRESS - Methods and compositions comprising N-acetylcysteine amide (NAC amide) and derivatives thereof are used in treatments and therapies for human and non-human mammalian diseases, disorders, conditions and pathologies. Pharmaceutically or physiologically acceptable compositions of NAC amide or derivatives thereof are administered alone, or in combination with other suitable agents, to reduce, prevent, or counteract oxidative stress and free radical oxidant formation and overproduction in cells and tissues, as well as to provide a new source of glutathione. | 05-13-2010 |
20100130616 | SALT OF ALISKIREN WITH OROTIC ACID - The invention relates to a new salt of aliskiren, the respective production and usage, and pharmaceutical preparations containing such a salt. | 05-27-2010 |
20100197793 | SOLID STATE FORMS OF ALISKIREN COMPOUNDS - The invention relates to solid states of pharmaceutically acceptable compounds of aliskiren, and processes for preparation thereof. The invention further provides pharmaceutical formulations comprising the amorphous or crystalline forms of pharmaceutically acceptable compounds of aliskiren and processes thereof; and a method of inhibiting renin for treating hypertension. | 08-05-2010 |
20100222432 | Synthetic Carbon Nanotubes - Methods to prepare synthetic carbon nanotubes having controllable properties and synthetic carbon nanotubes having controllable properties are provided. The properties which are controllable using the methods provided here include independently and in combination: diameter, length, identity and number of functional groups present and identity and number of heteroatoms present. | 09-02-2010 |
20100234467 | METHODS FOR IMPROVING BIOAVAILABILITY OF A RENIN INHIBITOR - The present invention provides a method for improving the bioavailability of a renin inhibitor, preferably, of a ε-amino-γ-hydroxy-ω-aryl-alkanoic acid derivative, which method comprises co-administering to a mammal, especially a human, in need of such treatment, a combination of a renin inhibitor, or a pharmaceutically acceptable salt thereof, and an MDR | 09-16-2010 |
20100240760 | Biomarkers for Efficacy of Aliskiren as a Hypertensive Agent - A retrospective pharmacogenetic analysis was conducted in an attempt to evaluate potential association between genetic variation and outcome of a clinical trial of efficacy of aliskiren as an antihypertensive agent. Forty-eight polymorphisms were examined in twelve genes from the renin-angiotensin-aldosterone system (RAS) or previously implicated in blood pressure regulation. Significant associations were seen between one polymorphism in the angiotensin converting enzyme (ACE) gene, two polymorphisms in the angiotensin II type 2 receptor (AGTR2) gene, and clinical parameters of mean sitting diastolic and systolic blood pressure decrease. These effects were not found with irbesartan and placebo treatment, but instead were specific to aliskiren treatment. | 09-23-2010 |
20100267834 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR DIFFERENTIALLY ALTERING GENE EXPRESSION TO PROVIDE NEUROPROTECTION FOR THE ANIMAL CENTRAL NERVOUS SYSTEM AGAINST THE EFFECTS OF ISCHEMIA, NEURODEGENERATION, TRAUMA AND METAL POISONING - Pharmaceutical compositions for treating and/or pre-treating or preconditioning the animal central nervous system against the effects of Alzheimer's Disease including the associated neurodegeneration and cognitive, behavioral and physical impairments. In one embodiment, an effective dose of deferoxamine (DFO) is administered to the upper one-third of the subject patient's nasal cavity to effectively bypass the blood-brain barrier, thereby allowing application of the DFO dose directly to the central nervous system. | 10-21-2010 |
20100286280 | INHIBITORS OF EPPIN/SEMENOGELIN BINDING AS MALE CONTRACEPTIVES - Compounds suitable for use in providing male contraception, an assay method for identifying such compounds, and methods of providing contraception using the compounds, are provided. The compounds described herein inhibit Eppin-semenogelin binding, and inhibit forward motility of sperm in humans and other primates. The assays identify compounds which both inhibit eppin-semenogelin binding and inhibit sperm motility, and can be carried out in a high throughput manner, using labeled recombinant Eppin and semenogelin. The compounds can be used in oral or transdermal compositions to temporarily and reversibly inhibit male fertility. They can also be used in addition to, or in place of, spermicides in spermicidal compositions, such as those used in conjunction with condoms, diaphragms, and spermicidal jellies. | 11-11-2010 |
20100292335 | USE OF ORGANIC COMPOUNDS - The present invention provides methods for the prevention of, delay of progression to or the treatment of diseases modulated by an increase in tissue bradykinin levels by administering to a warm-blooded animal a therapeutically effective amount of a renin inhibitor, or a pharmaceutically acceptable salt thereof, alone or in combination with (i)) an ACE inhibitor or a pharmaceutically acceptable salt thereof, (II) an angiotensin II receptor blocker, or a pharmaceutically acceptable salt of either. | 11-18-2010 |
20100324144 | THERAPY FOR HYPEREXCITABILITY DISORDERS - The present invention is directed to the use of a class of peptide compounds for treating diseases associated with hyperexcitability. The present invention is also directed to the use of a class of peptide compounds for treating diseases associated with dysfunction of an ion channel. | 12-23-2010 |
20100324145 | Crystalline ACAT Inhibitor - The invention is directed to the Form A polymorph of N-benzyl-N′-(2,6-diisopropyl-phenyl)-N-isopropyl-malonamide and its use as a therapeutic/cosmetic agent. | 12-23-2010 |
20110082210 | FATTY ACID FIBRATE DERIVATIVES AND THEIR USES - The invention relates to fatty acid fibrate derivatives; compositions comprising an effective amount of a fatty acid fibrate derivative; and methods for treating or preventing an metabolic disease comprising the administration of an effective amount of a fatty acid fibrate derivative. | 04-07-2011 |
20110082211 | METHOD FOR TREATING TINNITUS AUREUM - A method is described for treating tinnitus aureum in a subject by administering to the subject a therapeutically effective amount of a compound as defined in Formula I herein, illustratively (R)-2-acetamido-N-benzyl-3-methoxypropionamide, or a pharmaceutically acceptable salt thereof. | 04-07-2011 |
20110144209 | USE OF VASOCONSTRICTORS - There is disclosed the topical dermal use of vasocontrictor substances for regulating body temperature to treat cancer by inducing hyperthermia and treat, prevent or delay the onset of anesthetic induced hypothermia. Kits containing appropriate materials and instructions, and other embodiments, are also disclosed. | 06-16-2011 |
20110172309 | GALENIC FORMULATIONS OF ORGANIC COMPOUNDS - The present invention relates to a solid oral dosage form comprising a therapeutically effective amount of aliskiren or a pharmaceutically acceptable salt thereof, and wherein the active incredient is present in an amount of more than 46% by weight based on the total weight of the oral dosage form. | 07-14-2011 |
20110201687 | AMIDE DERIVATIVE, PEST CONTROL AGENT CONTAINING THE AMIDE DERIVATIVE, AND USE OF THE AMIDE DERIVATIVE - An amide derivative represented by the following Formula (1) is provided as an amide derivative showing a significantly excellent effect for a pest control action. | 08-18-2011 |
20110224303 | USE OF CI-994 AND DINALINE FOR THE TREATMENT OF MEMORY/COGNITION AND ANXIETY DISORDERS - The invention relates to methods and compositions for promoting cognitive function and/or treating cognitive function disorders and impairments. In particular the methods are accomplished by administering to a subject CI-994 or dinaline or a pharmaceutically acceptable salt, ester, prodrug or metabolite thereof. | 09-15-2011 |
20110245347 | METHOD FOR SELECTIVELY CRYSTALLIZING A Z ISOMER OF IOPROMIDE - The present invention relates to a method for selectively crystallizing Z isomer of iopromide of formula (I) comprising a) dissolving a crude iopromide comprising a mixture of E and Z isomers or a concentrate thereof in an alcohol, and b) heating the resulting alcohol solution to obtain crystalline of Z isomer of iopromide; and a method for preparing a composition comprising the crystalline Z isomer of iopromide. | 10-06-2011 |
20110263713 | POLYMORPHS - The present invention relates to crystalline forms of the active pharmaceutical ingredient vorinostat, processes for their preparation and their use in pharmaceutical compositions. Formula (I). | 10-27-2011 |
20110294892 | Use of histone deacetylase inhibitors for the care of Philadephia-negative myeloproliferative syndromes - The use of substances capable of inhibiting one or more enzymes of the histone deacetylase family (histone deacetylase inhibitors) for the therapeutic treatment of Philadelphia-negative myeloproliferative syndromes (polycythemia vera, essential thrombocythemia or idiopathic myelofibrosis) is described. The dosage of the above-mentioned substances is significantly lower than that normally used for the care of other tumor syndromes and may be from 10 to 150 mg/day/patient. | 12-01-2011 |
20110306668 | CONSTRUCTION AND SCREENING OF SOLUTION-PHASE DERIVED LIBRARY OF FENBUFEN AND ETHACRYNIC ACID - A process for synthesizing and screening solution phase derived libraries of fenbufen and ethacrynic acid is provided in the present invention. Compounds in the present invention having cytotoxicities are useful for a variety of therapeutic applications. | 12-15-2011 |
20120004311 | OPTICALLY PURE APOGOSSYPOL DERIVATIVE AS PAN-ACTIVE INHIBITOR OF ANTI-APOPTOTIC B-CELL LYMPHOMA/LEUKEMIA-2 (BCL-2) - A compound of Formula I: | 01-05-2012 |
20120004312 | Synergistic combinations comprising a renin inhibitor for cardiovascular diseases - The invention relates to a combination comprising the renin inhibitor of formula (I) | 01-05-2012 |
20120010295 | Synergistic combinations comprising a renin inhibitor for cardiovascular diseases - The invention relates to a combination comprising the renin inhibitor of formula (I) | 01-12-2012 |
20120016035 | Synergistic combinations comprising a renin inhibitor for cardiovascular diseases - The invention relates to a combination comprising the renin inhibitor of formula (I) | 01-19-2012 |
20120029083 | POLYMORPHIC FORMS OF ALISKIREN HEMIFUMARATE AND PROCESS FOR PREPARATION THEREOF - Provided are amorphous and polymorphic forms of aliskiren hemifumarate, pharmaceutical compositions thereof, and processes for their preparation. | 02-02-2012 |
20120041067 | Methods of Inducing Terminal Differentiation - The present invention provides methods of selectively inducing terminal differentiation, cell growth arrest and/or apoptosis of neoplastic cells, and/or inhibiting histone deacetylase (HDAC) by administration of pharmaceutical compositions comprising potent HDAC inhibitors. The oral bioavailability of the active compounds in the pharmaceutical compositions of the present invention is surprisingly high. Moreover, the pharmaceutical compositions unexpectedly give rise to high, therapeutically effective blood levels of the active compounds over an extended period of time. The present invention further provides a safe, daily dosing regimen of these pharmaceutical compositions, which is easy to follow, and which results in a therapeutically effective amount of the HDAC inhibitors in vivo. | 02-16-2012 |
20120083533 | USE OF AMIDES OF MONO- AND DICARBOXYLIC ACIDS IN THE TREATMENT OF RENAL DISEASES - A therapy for renal diseases, in particular renal diseases which develop in diabetic patients or patients who have been subjected to a treatment with an antitumor chemotherapy such as a platinum derivative and more generally cytotoxic drugs at renal level for treating of neoplastic diseases. More particularly, the present invention relates to palmitoylethanolamide and diethanolamide of fumaric acid for use in the treatment of renal diseases, in particular those caused by dysmetabolic diseases or by toxic or chemotherapy agents, such as platinum derivatives. Palmitoylethanolamide is used preferably in micronized or ultra-micronized form. Diethanolamide of fumaric acid is used preferably in aqueous solution. | 04-05-2012 |
20120142781 | Antagonists of the Magnesium Binding Defect as Therapeutic Agents and Methods for Treatment of Abnormal Physiological States - This invention provides a class of therapeutic compounds and methods for the treatment of mammals with physiological disorders, such as for example a frequently occurring type of essential hypertension, which are critically associated with the decreased binding of magnesium to the plasma membranes of their cells. These methods consist of administering to a mammal in need of such treatment a compound selected from a series of disubstituted trans, trans 1,3-butadienes, 1,3-disubstituted perhydrobutadienes, 1,2-disubstituted trans ethylenes and 1,2 disubstituted ethanes and disubstituted propanes, each of which embodies, in common, the unique structural feature essential for the biological activity of these compounds. This invention also provides for pharmaceutical formulations that employ these novel compounds. | 06-07-2012 |
20120178817 | COMPOSITIONS OF DIBROMOMALONAMIDE AND THEIR USE AS BIOCIDES - A biocidal composition comprising 2,2-dibromomalonamide and a surface active biocide, and its use for the control of microorganisms in aqueous and water-containing systems. | 07-12-2012 |
20120178818 | COMPOSITIONS OF DIBROMOMALONAMIDE AND THEIR USE AS BIOCIDES - A biocidal composition comprising 2,2-dibromomalonamide and sodium ortho-phenylphenol, and its use for the control of microorganisms in aqueous and water-containing systems. | 07-12-2012 |
20120220663 | SOLID FORMS OF ALISKIREN HEMIFUMARATE AND PROCESSES FOR PREPARATION THEREOF - The present invention provides polymorphic forms of aliskiren hemifumarate, and processes for preparation thereof and for the preparation of the amorphous form of aliskiren hemifumarate. The present invention also provides pharmaceutical compositions comprising the aliskiren hemifumarate crystalline forms T1, T3 or T4, T5, T6, T7, T8 and at least one pharmaceutically acceptable excipient, and the use of these pharmaceutical compositions in the treatment of hypertension. | 08-30-2012 |
20120252899 | METHOD OF REMOVING E. COLI BACTERIA FROM AN AQUEOUS SOLUTION - The method of removing | 10-04-2012 |
20120322878 | Polycationic Compounds And Uses Thereof - Aspects of the present invention relate to compounds and methods useful in modulating angiogenesis and methods of treating or preventing diseases associated with angiogenesis by administering a polycationic compound. The present invention relates to methods of use and compositions for inhibiting angiogenesis-mediated disorders in mammals including animals and humans. Additionally, this invention relates to the combined use of polycations with other anti-angiogenesis agents for the treatment of different angiogenesis-mediated disorders. Additionally, those polycationic compounds can be used with various anti-inflammatory and cytotoxic agents as well as with radio-therapeutic agents in cancer patients to prevent and treat tumor growth and metastasis. | 12-20-2012 |
20120322879 | USE OF CI-994 AND DINALINE FOR THE TREATMENT OF MEMORY/COGNITION AND ANXIETY DISORDERS - The invention relates to methods and compositions for promoting cognitive function and/or treating cognitive function disorders and impairments. In particular the methods are accomplished by administering to a subject CI-994 or dinaline or a pharmaceutically acceptable salt, ester, prodrug or metabolite thereof. | 12-20-2012 |
20130035394 | Calixarene-Based Peptide Conformation Mimetics, Methods of Use, and Methods of Making - A class of topomimetic calixarene-based peptide mimetics is described. Calixarene-based peptide mimetics have various biological activities such as, for example, bactericidal activity, antiangiogenic activity, and/or antitumor activity. Methods of use and methods of designing calixarene-based peptide mimetics are described. | 02-07-2013 |
20130046023 | PHARMACEUTICAL COMPOSITION CONTAINING GLUR2-LACKING AMPAR ANTAGONIST FOR PREVENTING OR TREATING PSYCHIATRIC ILLNESSES - A pharmaceutical composition, comprising a GluR | 02-21-2013 |
20130065964 | PERITONEAL DIALYSIS SOLUTION - The present invention relates to a type of peritoneal dialysis solution that comprises aliskiren or any of its derivatives, at least one electrolyte, at least one buffer solution and at least one osmotic agent. This enables toxicity reduction in these habitually used peritoneal dialysis solutions with respect to peritoneal mesothelial cells. On the other hand, the present invention relates to the use of these types of solutions in processes requiring peritoneal dialysis, as in the case of chronic renal failure. | 03-14-2013 |
20130102677 | NOVEL SOLID FORMS OF TACEDINALINE - Novel solid forms of tacedinaline (4-(acetylamino)-N-(2-aminophenyl)benzamide), including crystalline tacedinaline Forms A, B, and D, a novel crystalline tacedinaline TFA salt, and amorphous tacedinaline, are disclosed. Pharmaceutical compositions comprising crystalline tacedinaline Forms A, B, and D, the novel crystalline tacedinaline TFA salt, and/or amorphous tacedinaline, and methods of treating various conditions by administering those novel solid forms, are also disclosed. | 04-25-2013 |
20130150450 | NOVEL SOLID FORMS OF TACEDINALINE - Novel solid forms of tacedinaline (4-(acetylamino)-N-(2-aminophenyl)benzamide), including crystalline tacedinaline Forms A, B, and D, a novel crystalline tacedinaline TFA salt, and amorphous tacedinaline, are disclosed. Pharmaceutical compositions comprising crystalline tacedinaline Forms A, B, and D, the novel crystalline tacedinaline TFA salt, and/or amorphous tacedinaline, and methods of treating various conditions by administering those novel solid forms, are also disclosed. | 06-13-2013 |
20130172421 | USE OF KUKOAMINE A AND KUKOAMINE B - The use of Kukoamine A and Kukoamine B in the preparation of drugs for the prevention and treatment of sepsis and autoimmune disease is disclosed. Bacterial endotoxin/lipopolysaccaride (LPS) and unmethylated DNA (CpG DNA) of bacteria, the major pathogen-associated molecular patterns in sepsis and autoimmune disease, are specifically targeted, while the disclosed use directionally isolates lead compounds from traditional Chinese medicine. These measures can overcome the major defects of uncertainty of pharmacological material basis and drug targets of extracts and constituents of traditional Chinese medicine. The disclosed use can help in developing a safe, effective and quality controllable drug for prevention and treatment of sepsis and autoimmune disease so as to help solve the present lack of effective drugs in clinical treatment. | 07-04-2013 |
20130210918 | TREATMENT OF FRIEDREICH'S ATAXIA USING HISTONE DEACETYLASE INHIBITORS - The invention provides methods of treating Friedreich's ataxia using histone deacetylase inhibitors. | 08-15-2013 |
20130225686 | SOLID FORMS OF AN N-(PHENYLMETHYL) PROPANAMIDE DERIVATIVE AND PROCESSES OF PREPARATION - The invention relates to solid forms of the anti-epileptic agent lacosamide (I). The invention also relates to mixtures of solid forms of lacosamide. The invention further relates to mixtures of lacosamide enantiomers crystallized in a conglomerate Form and the use thereof in providing enantiomerically enriched lacosamide, preferably lacosamide enriched with the (R)-enantiomer of lacosamide. | 08-29-2013 |
20130231392 | AMIDE DERIVATIVE, PEST CONTROL AGENT CONTAINING THE AMIDE DERIVATIVE, AND USE OF THE AMIDE DERIVATIVE - An amide derivative represented by the following Formula (1) is provided as an amide derivative showing a significantly excellent effect for a pest control action. | 09-05-2013 |
20130310459 | AMIDE DERIVATIVE, PEST CONTROL AGENT CONTAINING THE AMIDE DERIVATIVE, AND USE OF THE AMIDE DERIVATIVE - An amide derivative represented by the following Formula (1) is provided as an amide derivative showing a significantly excellent effect for a pest control action. | 11-21-2013 |
20130317109 | PROCESS FOR THE PREPARATION OF LACOSAMIDE - There is provided a process for the preparation of Lacosamide (which is a useful medicament) of formula I, which comprises an enantioselective enzymatic acylation. | 11-28-2013 |
20140011882 | COMPOSITION OF 5-NITROBENZOATE DERIVATIVES AS ANTI-METASTATIC AGENT THAT INHIBITS TUMOR CELL-INDUCED PLATELET AGGREGATION - Disclosed are 5-nitrobenzoate derivatives of Formula I, | 01-09-2014 |
20140039059 | USE OF HISTONE DEACETYLASE INHIBITORS FOR THE CARE OF PHILADELPHIA-NEGATIVE MYELOPROLIFERATIVE SYNDROMES - The use of substances capable of inhibiting one or more enzymes of the histone deacetylase family (histone deacetylase inhibitors) for the therapeutic treatment of Philadelphia-negative myeloproliferative syndromes (polycythemia vera, essential thrombocythemia or idiopathic myelofibrosis) is described. The dosage of the above-mentioned substances is significantly lower than that normally used for the care of other tumour syndromes and may be from 10 to 150 mg/day/patient. | 02-06-2014 |
20140051763 | METHODS OF TREATING FRONTAL TEMPORAL DEMENTIA (FTD) WITH COMPRISING ADMINISTERING METAL CHELATORS TO THE UPPER ONE-THIRD OF THE NASAL CAVITY - The present invention comprises methods and pharmaceutical compositions for intranasal delivery of effective amounts of DFO directly to the CNS, in particular the brain treatments that inhibit GSK3b in patients with psychiatric disorders including, but not limited to, bipolar disorder, depression, ADHD and schizophrenia. In addition a treatment composition is disclosed which comprises DFO and in certain embodiments combines DFO with one or more of the psychotropic drug types, i.e., antipsychotics, mood stabilizers and antidepressants. Moreover, a treatment for treating impairment of neural plasticity through inhibition of GSK3b is provided as well as prevention of apoptosis of cells through inhibition of GSK3b. | 02-20-2014 |
20140057984 | METHODS OF TREATING CORTICOBASAL DEGENERATION COMPRISING ADMINISTERING METAL CHELATORS TO THE UPPER ONE-THIRD OF THE NASAL CAVITY - Methods for preconditioning and/or providing neuroprotection to the animal central nervous system against the effects of ischemia, trauma, metal poisoning and neurodegeneration, including the associated cognitive, behavioral and physical impairments. Patients diagnosed with, or at risk for, certain diseases or disorders that are associated with risk for cerebral ischemia may benefit, e.g., those at risk for Alzheimer's disease, Parkinson's disease, corticobasal degeneration, Wilson's disease or stroke or those patients having head or spinal cord injury. Intranasal therapeutic agents are administered to the upper third of the nasal cavity to bypass the blood-brain barrier and access the central nervous system directly to avoid unwanted and potentially lethal side effects. Therapeutic agents include those substances that interact with iron and/or copper such as iron chelators, copper chelators, and antioxidants. A particular example of such therapeutic agents is the iron chelator deferoxamine (DFO). | 02-27-2014 |
20140066515 | METHODS FOR TREATING CHANNELOPATHIES - The present invention is directed to the use of a class of peptide compounds for treating diseases associated with hyperexcitability. The present invention is also directed to the use of a class of peptide compounds for treating diseases associated with dysfunction of an ion channel. | 03-06-2014 |
20140094521 | BENZYLAMINE DERIVATIVE - The objective of the present invention is to provide a new compound which is effective in treating blood cancer, particularly multiple myeloma, and which is also effective in suppressing an SP cell, i.e. Side Population Cell, which is a cause of recurrence of cancer. The compound according to the present invention is a novel compound which has the specific benzylamine structure. | 04-03-2014 |
20140121278 | ANTI-TUMOR AGENT OTX-008 TARGETS HUMAN GALECTIN-1 - Disclosed herein are compositions comprising a galectin-1-targeting compound in a therapeutically effective composition for treating cancer. In an aspect, a galectin-1-targeting compound is OTX-008. Also disclosed herein are methods of making and using such compositions. | 05-01-2014 |
20140121279 | Enkephalin Analogues - The present invention relates to dipeptide enkephalin analogues of Formula (I) and their tautomers, ionic forms and pharmaceutically acceptable salts, and their use in medicine, in particular as opioid agonists. | 05-01-2014 |
20140135401 | ARACHIDONIC ACID ANALOGS AND METHODS FOR ANALGESIC TREATMENT USING SAME - The present invention provides arachidonic acid (AA) analogs and compositions containing those analogs as active agents for use in analgesic treatments. Various methods of manufacturing the inventive compounds are provided and pharmaceutical formulations, including injectable and oral dosages, are described. Certain analogs are additionally useful as antipyretic compositions and in related fever reducing treatments. | 05-15-2014 |
20140171508 | METHOD OF TREATING PARKINSON'S DISEASE COMPRISING ADMINISTERING DEFEROXAMINE (DFO) TO THE UPPER ONE-THIRD OF THE NASAL CAVITY - Methods and pharmaceutical compositions for preconditioning and/or providing neuroprotection to the animal central nervous system against the effects of ischemia, trauma, metal poisoning and neurodegeneration, including the associated cognitive, behavioral and physical impairments. In one embodiment, the method is accomplished by stimulating and stabilizing hypoxia-inducible factor-1α (HIF-1α). HIF-1α is known to provide a neuroprotective benefit under ischemic conditions. Patients at risk for certain diseases or disorders that are associated with risk for cerebral ischemia may benefit, e.g., those at risk for Alzheimer's disease, Parkinson's disease, Wilson's disease or stroke or those patients having head or spinal cord injury. Patients undergoing certain medical procedures that may result in ischemia may also benefit. Initially, the possibility of ischemia or neurodegeneration is recognized. Intranasal therapeutic agents are administered to the upper third of the nasal cavity to bypass the blood-brain barrier and access the central nervous system directly to avoid unwanted and potentially lethal side effects. Therapeutic agents include those substances that interact with iron and/or copper such as iron chelators, copper chelators, and antioxidants. A particular example of such therapeutic agents is the iron chelator deferoxamine (DFO). Intranasal administration of DFO is known to stimulate and/or stabilize HIF-1α and provides an efficient and safe method for pre-conditioning the brain to protect against cerebral ischemia. Moreover, DFO is shown to decrease weight loss in subjects when administered pre and/or post stroke. | 06-19-2014 |
20140179789 | METHODS OF TREATING HUNTINGTON'S DISEASE COMPRISING ADMINISTERING METAL CHELATORS TO THE UPPER ONE-THIRD OF THE NASAL CAVITY - Methods for preconditioning and/or providing neuroprotection to the animal central nervous system against the effects of Huntington's disease. Therapeutic agents are administered to the upper third of the nasal cavity to bypass the blood-brain barrier and access the central nervous system directly to avoid unwanted and potentially lethal side effects. Therapeutic agents include those substances that interact with iron and/or copper such as iron chelators, copper chelators, and antioxidants. A particular example of such therapeutic agents is the iron chelator deferoxamine (DFO). An effective amount of DFO may be administered to the upper third of the nasal cavity of a patient at risk for, or diagnosed with Huntington's disease. The effective amount of DFO is delivered directly to the patient's central nervous system for preconditioning, preventing and/or treating Huntingon's disease. | 06-26-2014 |
20140179790 | METHOD OF TREATING TRAUMATIC BRAIN INJURY/HEAD INJURY COMPRISING ADMINISTERING METAL CHELATORS TO THE UPPER ONE-THIRD OF THE NASAL CAVITY - Methods for treating the animal central nervous system for the effects of traumatic brain injury. Therapeutic agents are administered to the upper third of the nasal cavity to bypass the blood-brain barrier and access the central nervous system directly to avoid unwanted and potentially lethal side effects. Therapeutic agents include those substances that interact with iron and/or copper such as iron chelators, copper chelators, and antioxidants. A particular example of such therapeutic agents is the iron chelator deferoxamine (DFO). An effective amount of DFO may be administered to the upper third of the nasal cavity of a patient suffering from traumatic brain injury. The effective amount of DFO is delivered directly to the patient's central nervous system for treating the traumatic brain injury. | 06-26-2014 |
20140179791 | METHOD OF TREATING PROGRESSIVE SUPRANUCLEAR PALSY COMPRISING ADMINISTERING METAL CHELATORS TO THE UPPER ONE-THIRD OF THE NASAL CAVITY - Methods for preconditioning and/or providing neuroprotection to the animal central nervous system against the effects of progressive supranuclear palsy. Therapeutic agents are administered to the upper third of the nasal cavity to bypass the blood-brain barrier and access the central nervous system directly to avoid unwanted and potentially lethal side effects. Therapeutic agents include those substances that interact with iron and/or copper such as iron chelators, copper chelators, and antioxidants. A particular example of such therapeutic agents is the iron chelator deferoxamine (DFO). An effective amount of DFO may be administered to the upper third of the nasal cavity of a patient at risk for, or diagnosed with, progressive supranuclear palsy. The effective amount of DFO is delivered directly to the patient's central nervous system for preconditioning, preventing and/or treating the progressive supranuclear palsy. | 06-26-2014 |
20140179792 | METHOD OF TREATING LEWY BODY SYNDROME WITH COMPRISING ADMINISTERING METAL CHELATORS TO THE UPPER ONE-THIRD OF THE NASAL CAVITY - Methods for preconditioning and/or providing neuroprotection to the animal central nervous system against the effects of Lewy body syndrome. Therapeutic agents are administered to the upper third of the nasal cavity to bypass the blood-brain barrier and access the central nervous system directly to avoid unwanted and potentially lethal side effects. Therapeutic agents include those substances that interact with iron and/or copper such as iron chelators, copper chelators, and antioxidants. A particular example of such therapeutic agents is the iron chelator deferoxamine (DFO). An effective amount of DFO may be administered to the upper third of the nasal cavity of a patient at risk for, or diagnosed with, Lewy body syndrome. The effective amount of DFO is delivered directly to the patient's central nervous system for preconditioning, preventing and/or treating the Lewy body syndrome. | 06-26-2014 |
20140179793 | METHODS OF TREATING NEURODEGENERATION CAUSED BY IRON ACCUMULATION IN THE BRAIN COMPRISING ADMINISTERING METAL CHELATORS TO THE UPPER ONE-THIRD OF THE NASAL CAVITY - Methods for preconditioning, treating and/or providing neuroprotection to the animal central nervous system against the effects of neurodegeneration caused by iron accumulation in the brain. Therapeutic agents are administered to the upper third of the nasal cavity to bypass the blood-brain barrier and access the central nervous system directly to avoid unwanted and potentially lethal side effects. Therapeutic agents include those substances that interact with iron and/or copper such as iron chelators, copper chelators, and antioxidants. An examplary therapeutic agent is the iron chelator deferoxamine (DFO). An effective amount of DFO may be administered to the upper third of the nasal cavity of a patient at risk for or diagnosed with neurodegeneration caused by iron accumulation in the brain. The effective amount of DFO is delivered directly to the patient's central nervous system for preconditioning, preventing and/or treating neurodegeneration caused by iron accumulation in the brain. | 06-26-2014 |
20140187640 | N-ACETYLCYSTEINE AMIDE (NAC AMIDE) FOR THE TREATMENT OF DISEASES AND CONDITIONS ASSOCIATED WITH OXIDATIVE STRESS - Methods and compositions comprising N-acetylcysteine amide (NAC amide) and derivatives thereof are used in treatments and therapies for human and non-human mammalian diseases, disorders, conditions and pathologies. Pharmaceutically or physiologically acceptable compositions of NAC amide or derivatives thereof are administered alone, or in combination with other suitable agents, to reduce, prevent, or counteract oxidative stress and free radical oxidant formation and overproduction in cells and tissues, as well as to provide a new source of glutathione. | 07-03-2014 |
20140213656 | Plant Growth Regulator and Method for Using the Same - Provided is a novel plant growth regulator. The disclosed plant growth regulator comprises flubendiamide as an active ingredient. | 07-31-2014 |
20140221492 | DEUTERATED 2-AMINO-3-HYDROXYPROPANOIC ACID DERIVATIVES - This invention relates to novel 2-amino-3-hydroxypropanoic acid derivatives and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering an NMDA glycine-site antagonist. | 08-07-2014 |
20140235724 | AMIDE DENDRIMER COMPOSITIONS - Amide compounds, amide polymers, compositions including amide compounds and amide polymers may be used to bind target ions, such as phosphorous-containing compounds in the gastrointestinal tract of animals. In some cases, amide compounds and amide polymers may include a core derived from an amide polyol and an organic polyacid or ester. | 08-21-2014 |
20140275268 | NOVEL SOLID FORMS OF TACEDINALINE - Novel solid forms of tacedinaline (4-(acetylamino)-N-(2-aminophenyl)benzamide), including crystalline tacedinaline Form B, a novel crystalline tacedinaline TFA salt, and amorphous tacedinaline, are disclosed. Pharmaceutical compositions comprising crystalline tacedinaline Form B, the novel crystalline tacedinaline TFA salt, and/or amorphous tacedinaline, and methods of treating various conditions by administering those novel solid forms, are also disclosed. | 09-18-2014 |
20140275269 | Composition of 5-Nitrobenzoate Derivatives as Anti-Metastatic Agent that Inhibits Tumor Cell-Induced Platelet Aggregation - Disclosed are 5-nitrobenzoate derivatives of Formula I, | 09-18-2014 |
20140296344 | POLYUNSATURATED FATTY ACID MONOGLYCERIDES, DERIVATIVES, AND USES THEREOF - There are provided various polyunsaturated fatty acid monoglycerides and derivatives thereof. These compounds can be useful as cancer chemopreventive agents, cancer treating agent, inhibiting tumor growth or cell proliferation, reducing tumor growth or as radioenhencers for radiotherapy of cancer. | 10-02-2014 |
20150038586 | USE OF N-ACETYLCYSTEINE AMIDE IN THE TREATMENT OF PENETRATING HEAD INJURY - This disclosure describes methods of use for N-acetylcysteine amide for the treatment of penetrating head injury. | 02-05-2015 |
20150065576 | USE OF AMIDES OF MONO- AND DICARBOXYLIC ACIDS IN THE TREATMENT OF RENAL DISEASES - A therapy for renal diseases, in particular renal diseases, which develop in diabetic patients or patients who have been subjected to a treatment with an antitumor chemotherapy such as a platinum derivative and more generally cytotoxic drugs at renal level for treating of neoplastic diseases. More particularly, palmitoylethanolamide and diethanolamide of fumaric acid are used in the treatment of renal diseases, in particular those caused by dysmetabolic diseases or by toxic or chemotherapy agents, such as platinum derivatives. Palmitoylethanolamide is used preferably in micronized or ultra-micronized form. Diethanolamide of fumaric acid is used preferably in aqueous solution. | 03-05-2015 |
20150080472 | TREATMENT OF FRIEDREICH'S ATAXIA USING HISTONE DEACETYLASE INHIBITORS - The invention provides methods of treating Friedreich's ataxia using histone deacetylase inhibitors. | 03-19-2015 |
20150133558 | USE OF N-ACETYLCYSTEINE AMIDE FOR DECREASING INTRACRANIAL PRESSURE - This disclosure describes methods of use for N-acetylcysteine amide for the treatment of penetrating head injury. | 05-14-2015 |
20150148423 | USE OF N-ACETYLCYSTEINE AMIDE IN THE TREATMENT OF DISEASE AND INJURY - This disclosure describes methods of use for N-acetylcysteine amide for the treatment of various disorders | 05-28-2015 |
20150297541 | COMPOSITION AND METHOD FOR EXTERMINATING ANIMAL PARASITE - A composition for exterminating an animal parasite, the composition including, as an active ingredient, at least one of 3-aminoxalylaminobenzamide derivatives represented by the following Formula (1): | 10-22-2015 |
20150359762 | COMPOSITION AND METHOD FOR THE TREATMENT OF NEUROLOGICAL DISEASES AND CEREBRAL INJURY - Methods and compositions which include or include the administration of a hydrophobic drug, prodrug thereof, salt thereof, isoform thereof, or a combination thereof; cyclodextrin, prodrug thereof, salt thereof, or a combination thereof; polyethylene glycol, propylene glycol, or combination thereof; and optionally, a pharmaceutically acceptable carrier. | 12-17-2015 |
20160023990 | NON-PEPTIDE BDNF NEUROTROPHIN MIMETICS - Methods and compounds for treating neurological and other disorders are provided. Included is the administering to a subject in need thereof an effective amount of a compound having binding and/or modulation specificity for a TrkB receptor molecule. | 01-28-2016 |
20160031801 | DEUTERATED 2-AMINO-3-HYDROXYPROPANOIC ACID DERIVATIVES - This invention relates to novel 2-amino-3-hydroxypropanoic acid derivatives and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering an NMDA glycine-site antagonist. | 02-04-2016 |
20160031803 | OLIGO-BENZAMIDE COMPOUNDS AND THEIR USE IN TREATING CANCERS - The present invention includes bis- and tris-benzamide compounds that block AR signaling and have activity against prostate cancer. Uses for these compounds, and pharmaceutical compositions containing the same, also are provided. | 02-04-2016 |
20160038443 | CERAMIDE-LIKE FUNCTION IMPARTING AGENT - Provided are an agent for imparting ceramide-like function, | 02-11-2016 |
20160096800 | MODULATORS OF THE EIF2ALPHA PATHWAY - Provided herein, inter alia, are compounds and methods useful for modulating the translational effects of eIF2α phosphorylation, the Integrated Stress Response (ISR), and the unfolded protein response (UPR); for treating diseases; for increasing protein production, and for improving long-term memory. | 04-07-2016 |
20160151314 | Facially Amphiphilic Polymers and Oligomers and Uses Thereof | 06-02-2016 |
20160165884 | COMPOSITIONS OF DIBROMOMALONAMIDE AND THEIR USE AS BIOCIDES | 06-16-2016 |